accept responsibility for [the registrant's] actions and demonstrate that [registrant] will not engage in future misconduct.''' *Jayam Krishna-Iyer,* 74 FR at 463 (quoting *Medicine Shoppe,* 73 FR 364, 387 (2008)); *see also Jackson,* 72 FR at 23,853; *John H. Kennnedy, M.D.,* 71 FR 35,705, 35,709 (2006); *Prince George Daniels, D.D.S.,* 60 FR 62,884, 62,887 (1995). The issue of trust is necessarily a fact-dependent determination based on the circumstances presented by the individual respondent; therefore, the Agency looks at factors, such as the acceptance of responsibility, and the credibility of that acceptance as it relates to the probability of repeat violations or behavior, and the nature of the misconduct that forms the basis for sanction, while also considering the Agency's interest in deterring similar acts. *See Arvinder Singh, M.D.,* 81 FR 8247, 8248 (2016).

Regarding all of these matters, I agree with the analyses and conclusions contained in the R.D.'s Recommendation. R.D., at 56–59.

Here, the Respondent has accepted absolutely no responsibility for her actions. Regarding the allegations of her lapsed MCSR, she testified and presented evidence that she had relied to her detriment on a previous employer to file on her behalf; however, she also demonstrated that she had knowledge, and, possibly even contrary to her testimony, that she knew directly from the state, that her MCSR had not been renewed in October; and yet, she still continued prescribing controlled substances without obtaining a new MCSR until February. Tr. 524–69; RX 2; *see also* R.D., at 56–57 (''[H]er testimony and her reliance on the email correspondence with [her employer] leave no doubt that she continues to adhere to her position that the former bears all the blame, and she bears none.'')

Additionally, Respondent took no responsibility for the allegations related to her prescribing practices. Instead, she provided vague theories about evidence tampering, unfinished charts and testified that the Government's exhibits were ''not [her] typical notes.'' Tr. 574–75, 610, 616; *see also* R.D., at 57. She offered no intention of instituting remedial measures. ''There was no indication from the Respondent that she planned to, or already had, improved her recordkeeping practices when issuing prescriptions for powerful controlled substance medications.'' R.D., at 57.

In sum, I find that the record supports the imposition of a sanction because the Respondent did not unequivocally accept responsibility.

In sanction determinations, the Agency has also historically considered its interest in deterring similar acts, both with respect to the respondent in a particular case and the community of registrants as a whole. *See Joseph Gaudio, M.D.,* 74 FR 10,083, 10,095 (2009); *Singh,* 81 FR at 8248. Here, the interests of specific and general deterrence ''militate in favor of revocation.'' R.D., at 58. Respondent has evidenced no understanding that her controlled substance prescribing fell short of legal requirements.

> To the extent that her progress notes fail to establish an adequate basis for prescribing powerful controlled drugs, she chalks that up to the risks attendant upon the practice of a busy prescriber, and she fails to recognize any significance of prescriptions issued before the patient's previous medication supply would have been exhausted.

R.D., at 58–59. As such, it is not reasonable to believe that Respondent's future prescribing will comply with legal requirements. Further, given the number of Respondent's violations, a sanction less than revocation would send a message to the regulated community that ''so long as there is another person available to blame for failing to file required paperwork, and a busy . . . practice to blame for inadequate documentation,'' compliance with the law is not a condition precedent to maintaining a registration. *Id.* at 59.

In evaluating the egregiousness of Respondent's conduct, I agree with the Chief ALJ that although ''the record did not paint the picture of a pill mill operator, this Respondent failed to exercise the level of care in prescribing and documenting her prescribing decisions that would allow a meaningful evaluation by those charged with regulating controlled substances.'' *Id.* Throughout the hearing, she vehemently protested against any acceptance of responsibility, consistently pinning blame on everyone and anyone else, even when entirely implausible, and unsupported by the evidence, and she demonstrated a general disdain for the charges against her and the situation in which she had found herself. *Id.*

Accordingly, I find that the factors weigh in favor of sanction and I shall order the sanctions the Government requested, as contained in the Order below.

Order

Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(f) and 824(a), I hereby revoke DEA Certificate of Registration No. MH0525153 issued to Lisa Hamilton, N.P. I further hereby deny any pending application of Lisa Hamilton, N.P. to renew or modify this registration, as well as any other pending application of Lisa Hamilton, N.P. for registration in Massachusetts. This Order is effective January 27, 2020. ins

Dated: December 4, 2019.

Uttam Dhillon,

Acting Administrator.

[FR Doc. 2019–27945 Filed 12–26–19; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–572]

Importer of Controlled Substances Application: Siegfried USA, LLC

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 27, 2020. Such persons may also file a written request for a hearing on the application on or before January 27, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on November 6, 2019, Siegfried USA, LLC, 33 Industrial Park Road, Pennsville, New Jersey 08070 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Opium, raw	9600	II
Poppy Straw Concentrate.	9670	II

The company plans to import the listed controlled substances to manufacture bulk active pharmaceutical ingredients (API) for distribution to its customers.

Dated: December 10, 2019.

William T. McDermott,

Assistant Administrator.

[FR Doc. 2019–27953 Filed 12–26–19; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–552]

Importer of Controlled Substances Application: Myoderm

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 27, 2020. Such persons may also file a written request for a hearing on the application on or before January 27, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on October 14, 2019, Myoderm, 48 East Main Street, Norristown, Pennsylvania 19401–4915 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Amphetamine	1100	II
Lisdexamfetamine	1205	II
Methylphenidate	1724	II
Nabilone	7379	II
Oxycodone	9143	II
Hydromorphone	9150	II
Hydrocodone	9193	II
Morphine	9300	II
Oxymorphone	9652	II
Fentanyl	9801	II

The company plans to import the listed controlled substances for clinical trials, research, and analytical purposes. Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale.

Dated: November 13, 2019.

William T. McDermott,

Acting Assistant Administrator.

[FR Doc. 2019–27954 Filed 12–26–19; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–566]

Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before February 25, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on October 9, 2019, Janssen Pharmaceuticals Inc., Buildings 1–5 & 7–14, 1440 Olympic Drive, Athens, Georgia 30601 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Methylphenidate	1724	II
Hydromorphone	9150	II
Hydrocodone	9193	II
Oripavine	9330	II
Thebaine	9333	II
Tapentadol	9780	II

The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers.

Dated: December 10, 2019.

William T. McDermott,

Assistant Administrator.

[FR Doc. 2019–27952 Filed 12–26–19; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF LABOR

Employment and Training Administration

Notice To Ensure State Workforce Agencies Are Aware of the Revised Schedule of Remuneration for the Unemployment Compensation for Ex-Service Members (UCX) Program That Reflects the Military Pay Increase Effective January 1, 2020

AGENCY: Employment and Training Administration, Labor.

ACTION: Notice.

SUMMARY: Each year, the Department of Defense issues a Schedule of Remuneration used by states for UCX purposes. States must use the schedule to determine Federal military wages for UCX ''first claims'' only when the Federal Claims Control Center (FCCC) responds to a request for information indicating that there is no Copy 5 of the